Abstract
Lymphangioleiomyomatosis (LAM) is a rare, progressive lung disease with neoplastic traits, primarily driven by mutations in the TSC2 gene, which lead to hyperactivation of the mTOR pathway and uncontrolled cell growth. However, additional mutations may contribute to disease progression. In this study, we investigate the potential role of co-mutations, focusing on the FGFR4 p.Gly388Arg polymorphism, which has previously been associated with aggressive cancer progression, as a possible co-driver in LAM. Peripheral blood mononuclear cells (PBMCs) were isolated from seven sporadic LAM patients and analyzed using Next-Generation Sequencing (NGS) to identify tumorigenic mutations. The FGFR4 p.Gly388Arg variant was identified in four patients, with allelic frequencies ranging from 49% to 99%. The highest frequency was observed in a patient with severe bullous lung disease, who ultimately required lung transplantation. Our analysis revealed a strong positive correlation (r = 0.85, p = 0.15) between FGFR4 allelic frequency and lung function decline (FEV1%), as well as a moderate positive correlation (r = 0.55, p = 0.20) between FGFR4 mutation status (presence vs. absence) and FEV1% decline. Although these correlations did not reach statistical significance, the trends suggest that FGFR4 mutations may contribute to disease progression in LAM. These findings indicate that FGFR4 mutations could play a role in the systemic nature of LAM, potentially exacerbating disease severity. Further research is needed to evaluate FGFR4 as a biomarker and therapeutic target in conjunction with mTOR inhibitors for the treatment of LAM.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the German Research Foundation (DFG) (Grant No. KO5803/2-1 to SKG), the Federal Ministry for Research and Education Germany (BMBF) (Grant No. 01EO2102 to SKG) and departmental funds from the Department of Internal Medicine, Goethe University Frankfurt.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Written informed consent was obtained from all patients and the study was approved by the Institutional Review Boards of the University Cancer Center (UCT) and the Ethics Committee at the University Hospital Frankfurt (project number: STO-02-2017).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
The revision has updated information and is longer. It has been adapted from a Research Letter Format to a Brief Research Report.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
